Value-Based Contracting Between Insurers and Drug Companies Faces Tough Hurdles | Managed Care Magazine Online

When Harvard Pilgrim Health Care recently unveiled value-based contracts for two expensive medications, etanercept (Enbrel) and teriparatide (Forteo), the news caused a stir

Source: Value-Based Contracting Between Insurers and Drug Companies Faces Tough Hurdles | Managed Care Magazine Online

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s